Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market. What Are Smart ...

Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio ...

Fri, April 3, 2026 at 2:17 PM UTC The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion ...

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December 20, ...

From broad domestic exposure to global pharma and biotech, these funds cover the healthcare sector's main themes.

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

BBP specializes in pure biotechnology companies that have a marketable product. The fund stands to see significant capital gains from the acquisition of companies in its portfolio. A new ETF, BBP is ...

As anyone in the biotech investing space can tell you, picking winners in this corner of the healthcare market can be extremely difficult. Failed trials, FDA concerns, and pricing issues have hit a ...